Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Tech medical breakthrough

Candela Nordlys Laser Reverses Skin Aging

Analysis based on 9 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The market for medical aesthetic devices and regenerative medicine is expected to see increased interest and investment due to the scientific validation of Candela Corporation's Nordlys laser. This breakthrough could lead to higher demand for Candela Corporation's products and potentially influence research and development in related fields, benefiting companies like Mitra Bio involved in epigenetic research.

medical aesthetics biotechnology healthcare

A new peer-reviewed study published in Scientific Reports (Nature Portfolio) provides the first in vivo human evidence that Candela Corporation's Nordlys 1940 nm non-ablative fractional laser remodels the skin's epigenome, reversing age-associated DNA methylation. The research, conducted in partnership with Mitra Bio and the Candela Institute for Excellence, demonstrated that the treatment not only improves visible signs of aging but also has a direct molecular link to skin cancer biology by positively modulating DNA methylation at keratinocyte-regulating loci. The study involved 22 adults over nine months, showing progressive and durable molecular changes that paralleled visible improvements in brown spots, texture, and overall pigmentation.

priv
Candela Corporation is the developer and manufacturer of the Nordlys laser, which has been shown in a new study to reverse skin aging at a molecular level and have a link to skin cancer biology. This breakthrough enhances the company's reputation and product value.
Importance 100.0 Sentiment 75.0
priv
Mitra Bio partnered with Candela Corporation on the study, contributing to the scientific rigor and findings. This collaboration boosts Mitra Bio's profile in epigenetic research.
Importance 70.0 Sentiment 60.0
per
Konika Patel Schallen, MD, is the lead author of the study and SVP of Global Clinical Operations at Candela Corporation. Her involvement highlights the company's scientific leadership.
Importance 40.0 Sentiment 50.0
per
Dr. Cristiana Baniță, Chief Scientific Officer and co-founder of Mitra Bio, co-authored the study, emphasizing Mitra Bio's expertise in epigenetics.
Importance 40.0 Sentiment 50.0
per
Geoff Crouse, CEO of Candela Corporation, commented on the study's significance, reinforcing Candela's commitment to science-based innovation.
Importance 30.0 Sentiment 50.0
priv
Apax Partners acquired Candela Corporation in 2017. This event indirectly benefits Apax Partners through the increased value of its portfolio company.
Importance 10.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.